Lung Cancer
D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
- Details
ClinicalTrials.gov ID:
NCT03833154
Diagnosis Type:
NSCLC
USOR Number:
- Address
,
P: